StockCIK 1658551
Amylyx Pharmaceuticals, Inc. (AMLX): Insider Trades and Fund Holdings
In the past 12 months, Amylyx Pharmaceuticals, Inc. insiders reported 0 open-market purchases worth $0 and 6 sales worth $3.78M; 1 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$3.78MSold by insiders, 12 months
0Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 7, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 7 | George M. Milne JrDirector | ▼ SELL10b5-1 | $831K |
| Sep 14 | Joshua B. CohenCEO | ▼ SELL | $981K |
| Sep 14 | Justin B. KleeCEO | ▼ SELL | $980K |
| Sep 14 | James M. FratesCFO | ▼ SELL | $350K |
| Sep 14 | Camille L. BedrosianChief Medical Officer | ▼ SELL | $325K |
| Sep 14 | Gina MazzarielloGeneral Counsel | ▼ SELL | $310K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| George M. Milne Jr | Director | 0 | $0 | 1 | $831K |
| Joshua B. Cohen | CEO | 0 | $0 | 1 | $981K |
| Justin B. Klee | CEO | 0 | $0 | 1 | $980K |
| James M. Frates | CFO | 0 | $0 | 1 | $350K |
| Camille L. Bedrosian | Chief Medical Officer | 0 | $0 | 1 | $325K |
| Gina Mazzariello | General Counsel | 0 | $0 | 1 | $310K |
ADVERTISEMENT
320 × 100 ad slot
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →